# Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

> **NCT05193617** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 104 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** GP+Penpulimab+Anlotinib
- **DRUG:** GP+Penpulimab

## Key facts

- **NCT ID:** NCT05193617
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-20
- **Primary completion:** 2025-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05193617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05193617, "Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05193617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*